Clinical trials: FOOD ALLERGY
Peanut Allergy
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
- Trial name
- ARC001 (NCT01987817)
- Testing
- AR101 powder provided in capsules
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aimmune Therapeutics, Inc.
Food Allergy
Infants Fed an Amino Acid-based Formula
To observe the effects of an amino acid-based formula on symptoms associated with food allergies in infants.
- Trial name
- NCT04127656
- Testing
- Amino Acid-Based Experimental Study Formula
- Where
- 3 sites in United Kingdom
- Volunteers
- 26 people
- Sponsor
- Abbott Nutrition
Peanut Allergy
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Open-label, follow-up study for subjects who completed the EPITOPE study.
- Trial name
- EPOPEX (NCT03859700)
- Testing
- DBV712 250 mcg
- Where
- 26 sites in United States
- Volunteers
- 304 people
- Sponsor
- DBV Technologies
Peanut Allergies
Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients
This study will evaluate the safety and efficacy of LP-003 for an increasing the amount of peanut protein that people with a peanut allergy can tolerate without having allergic symptoms.
- Trial name
- NCT07785063
- Testing
- LP-003 Injection
- Volunteers
- 80 people
- Sponsor
- Longbio Pharma (Suzhou) Co., Ltd.
Peanut Allergy
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in…
- Trial name
- NCT04950504
- Testing
- CNP-201
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Peanut Allergies
Flow CAST® Peanut Trial
This will be a multi-center, prospective evaluation, conducted at a minimum of four (4) U.S. sites. Sites will enroll peanut allergic subjects, subjects with allergies other than peanut and apparently healthy non-atopic control…
- Trial name
- NCT07775430
- Testing
- Basophil activation test
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Bühlmann Laboratories AG
Anaphylaxis Food
FMXIN002 in Patients at Risk of Anaphylaxis
Study Objective To evaluate the efficacy of FMXIN002, a powder-based intranasal epinephrine spray, for treating anaphylaxis. Study Design Hypothesis: FMXIN002 will terminate anaphylactic reactions as effectively-or more…
- Trial name
- NCT07045701
- Testing
- Epinephrine 4mg nasal powder spray, Adrenalin 0.5mg Injectable Product
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Nasus Pharma
Peanut Allergy
Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous…
- Trial name
- PEPITES (NCT02636699)
- Testing
- Viaskin Peanut 250mcg
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 500 people
- Sponsor
- DBV Technologies
Peanut Allergy
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.
- Trial name
- NCT02920021
- Testing
- Etokimab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- AnaptysBio, Inc.
Food Allergy
Long-term Extension Study of Ligelizumab in Food Allergy
This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.
- Trial name
- NCT05678959
- Testing
- Ligelizumab 120 mg, Ligelizumab 240 mg
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Eosinophilic Esophagitis (EoE)
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT05485779
- Testing
- AQ280
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Cow's Milk Protein Allergy (CMPA)
TeriFort 1+ Study: Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study (TeriFort 1+)
This study aims to evaluate the clinical effect, as reported by physicians, of an extensively hydrolyzed formula in young children aged 1~3 years with diagnosed with or highly suspected CMPA in a real-world clinical practice…
- Trial name
- NCT07855796
- Testing
- Diagnosed with or highly suspected CMPA: Extensively Hydrolyzed Formula intervention
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Teyi Yinuo Health Technology Co., Ltd.
Milk Hypersensitivity
Tolerability and Safety of An Infant Formula
The purpose of this study is to evaluate an extensively hydrolyzed formula in infants with cow's milk allergy.
- Trial name
- NCT00938483
- Testing
- Nutramigen Lipil (Infant formula)
- Volunteers
- 108 people
- Sponsor
- Perrigo Nutritionals